Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
05/2005
05/10/2005US6891027 Composition for use in the modulation of immunological response
05/10/2005US6891021 Regulated apoptosis
05/10/2005US6891009 Water-soluble or water-swellable crosslinked copolymers
05/10/2005US6890961 Applying topically to the leukoplakia lesion an effective amount of a clear aqueous formulation comprising: water; a water miscible polyol; unsaturated fatty acid ester; a surfactant, and beta -carotene
05/10/2005US6890957 Liquid formulation of metformin
05/10/2005US6890950 Complex with cyclodextrins; antitumor, anticancer agents
05/10/2005US6890948 With an electron withdrawing substituent; Treating neoplastic diseases in methods of GDEPT, ADPET, PDEPT, VDEPT, and PDT; tissue-directed prodrug therapy
05/10/2005US6890918 Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers
05/10/2005US6890911 Method for the treatment of inflammation
05/10/2005US6890901 Hyaluronic drug delivery system
05/10/2005US6890897 In combination with an osteoinductive protein and a bone morphogenetic protein or a hedgehog protein to induce osteogenesis; biocompatible or biodegradable matrix
05/10/2005US6890567 Sensate composition imparting initial sensation upon contact
05/10/2005US6890560 Negatively charged amphiphilic block copolymer as drug carrier
05/10/2005US6890559 Directly compressible raw material for tablets
05/10/2005US6890557 A film forming emulsions comprising triglycerides, cholesterol, phospholipids, an charged lipid, and water; drug delivery with an apoprotein, deliverying nucleic acid, a gene therapy
05/10/2005US6890545 Fungicide and method for producing the same
05/10/2005US6890544 A formualtion for topical administration containing (a) a corticosteroid, and (b) a drying agent selected from calamine, zinc containing drying agents, copper sulfate, kaolin, potassium permanganate, silver nitrate, starch, talc
05/10/2005US6890524 Hydrolyzable delivery system using cross-linked polymeric resins as vehicles
05/10/2005US6890518 Compositions of chemically modified insulin
05/10/2005US6890512 Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
05/10/2005CA2279743C Pharmaceutical composition of hedgehog proteins and use thereof
05/10/2005CA2251987C Microparticles
05/10/2005CA2232541C Fractionated vegetable oil
05/10/2005CA2222995C Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides
05/10/2005CA2183367C Ready-to-use indomethacin collyre
05/10/2005CA2159353C Microcapsules with walls made of cross-linked plant polyphenols, and compositions containing same
05/10/2005CA2153856C Duloxetine enteric pellets
05/10/2005CA2116192C Highly concentrated tcf pharmaceutical preparations
05/06/2005WO2005040382A2 Cherkasky fusion proteins containing antibody-, antigen- and microtubule-binding regions and immune response-triggering regions
05/06/2005WO2005040365A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
05/06/2005WO2005040353A2 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv
05/06/2005WO2005040352A2 Immunogenic composition and method of developing a vaccine based on factor h binding sites
05/06/2005WO2005040349A2 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
05/06/2005WO2005040342A2 Cleavage of rna by restriction endonucleases
05/06/2005WO2005040228A2 Disintegratable films for diagnostic devices
05/06/2005WO2005040100A1 Tetrahydro-naphthalene and urea derivatives
05/06/2005WO2005039641A2 Biomacromolecule polymer conjugates
05/06/2005WO2005039620A1 Stable aqueous g-csf-containing compositions
05/06/2005WO2005039616A1 Angiogenic peptides and uses thereof
05/06/2005WO2005039605A1 Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof
05/06/2005WO2005039602A1 Pharmacologically functional water and use thereof
05/06/2005WO2005039558A1 Targeted delivery of therapeutically active compounds
05/06/2005WO2005039553A1 Compositions for the treatment and prevention of cancer
05/06/2005WO2005039552A2 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives
05/06/2005WO2005039541A1 Coenzyme q10 enclosing capsule
05/06/2005WO2005039532A1 Microemulsions of retinoids, and pharmaceutical compositions containing them
05/06/2005WO2005039531A1 Transdermal pharmaceutical formulation for minimizing skin residues
05/06/2005WO2005039525A1 Skin care and cleansing compositions containing oil seed product
05/06/2005WO2005039501A2 Immunogenic composition and method of developing a vaccine based on fusion protein
05/06/2005WO2005039499A2 Rapidly disintegrating film
05/06/2005WO2005039495A2 Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
05/06/2005WO2005039464A1 Transdermal high and low molecular weight compounds
05/06/2005WO2005027895A3 Thyroid hormone analogs and methods of use in angiogenesis
05/06/2005WO2005023834A3 Peptides and compounds that bind to thrombopoietin receptors
05/06/2005WO2005009436A8 Dispersible formulation of an anti-inflammatory agent
05/06/2005WO2005003775A3 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
05/06/2005WO2005002626A8 Therapeutic phosphonate compounds
05/06/2005WO2004112482A8 Biological active coating components, coatings, and coated surfaces
05/06/2005WO2004105702A3 Foamable pharmaceutical compositions and methods for treating a disorder
05/06/2005WO2004100994A3 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
05/06/2005WO2004091539A3 Fluid mixing methods and apparatus
05/06/2005WO2004091537A3 Process for making gel films
05/06/2005WO2004091495A3 Compositions and methods related to production of erythropoietin
05/06/2005WO2004084807A3 Micro-cluster compositions
05/06/2005WO2004081533A3 Vault and vault-like carrier molecules
05/06/2005WO2004080383B1 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
05/06/2005WO2004078933A3 Intracellular delivery of small molecules proteins and nucleic acids
05/06/2005WO2004062614A3 Carbohydrate conjugates to prevent abuse of controlled substances
05/06/2005WO2004035537A8 Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
05/06/2005WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof
05/06/2005CA2543454A1 Drug-containing coated microparticles for quick-disintegrating oral tablets
05/06/2005CA2542967A1 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives
05/06/2005CA2542708A1 Dna delivery with gemini cationic surfactants
05/06/2005CA2542494A1 Tetrahydro-naphthalene and urea derivatives
05/06/2005CA2541511A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
05/06/2005CA2541506A1 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv
05/06/2005CA2541501A1 Immunogenic composition and method of developing a vaccine based on factor h binding sites
05/06/2005CA2541497A1 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
05/06/2005CA2541492A1 Immunogenic composition and method of developing a vaccine based on fusion protein
05/06/2005CA2540539A1 A mixture for transdermal delivery of low and high molecular weight compounds comprising an ethoxylated oil
05/06/2005CA2539650A1 Skin care and cleansing compositions containing oil seed product
05/05/2005US20050096479 Novel succinate salt of O-desmethyl-venlafaxine
05/05/2005US20050096446 Tri-block copolymers and a process for the preparation of the same
05/05/2005US20050096388 Compositions and methods for treating or preventing diseases of body passageways
05/05/2005US20050096371 Topical pharmaceutical compositions
05/05/2005US20050096365 Pharmaceutical compositions with synchronized solubilizer release
05/05/2005US20050096340 lipophilic derivatives of paclitaxel, camptothecin, docetaxel or derivatives thereof; tocopherol succinate paclitaxel for example; emulsions for drug delivery, treating cancer; increased plasma elimination half-life compared to the parent therapeutic drug
05/05/2005US20050096314 Treatment of cancers with methylol-containing compounds and at least one electrolyte
05/05/2005US20050096298 Purine compounds for treatment of bone disorders or cancer
05/05/2005US20050096296 Solubility of drugs is enhanced with solubilizers for drugs such as pioglitazone, zafilukast, simvastatin, atarvastin or fenofifrate
05/05/2005US20050096287 Enhance delivery of oligonucleotides, nucleosides, nucleic acids by injection or applying on skin a solution in water
05/05/2005US20050096284 RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
05/05/2005US20050096277 Methods of prevention and treatment using apolipoprotein analogues
05/05/2005US20050096261 Dna-binding polyamide drug conjugates
05/05/2005US20050096254 Peptide deformylase activated prodrugs
05/05/2005US20050095684 Protein fusion comprising colony stimulating factor activity for use as tool in rapid stimulation and production of white blood cells and neutrophils
05/05/2005US20050095304 Composition and method for smoke detoxification
05/05/2005US20050095298 Three dimensionally crosslinked agarose bead with grass pollen covalently bound; immunotherapy, vaccines, diagnosis
05/05/2005US20050095297 Nanoparticulate formulations of fenofibrate
05/05/2005US20050095293 Bioavailability of drug independent of gastric pH; core comprised of water soluble acid(s) of tartaric acid, fumaric acid, succinic acid, citric acid, malic acid, glutamic acid, and/or aspartic acid or salts; acid resistance; drug delivery